Over the past 12 months, 1 insider at Lineage Cell Therapeutics, Inc. filed 1 open-market SEC Form 4 transaction on LCTX: 1 purchase worth $24K and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on Mar 12, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 26 | Brian M CulleyPresident and CEO | BUY | 15.0K | $1.63 | $24K |
| Jan 27, 25 | Broadwood Capital IncTenPercentOwner | BUY | 7.89M | $0.76 | $6.0M |
| Nov 26, 24 | Jill Ann HoweChief Financial Officer | BUY | 15.0K | $0.59 | $9K |
| Nov 26, 24 | George A. Samuel IIIGeneral Counsel | BUY | 15.0K | $0.60 | $9K |
| Nov 22, 24 | Michael H. MulroyDirector | BUY | 40.0K | $0.57 | $23K |
| Nov 21, 24 | Brian M CulleyPresident and CEO | BUY | 40.0K | $0.60 | $24K |
| Aug 16, 24 | Jill Ann HoweChief Financial Officer | BUY | 10.5K | $0.89 | $9K |
| May 24, 24 | Brian M CulleyPresident and CEO | BUY | 10.0K | $1.05 | $11K |
| Feb 8, 24 | Don M BaileyDirector | BUY | 96.2K | $1.04 | $100K |
| Feb 6, 24 | Broadwood Partners, L.p.Director,TenPercentOwner | BUY | 6.73M | $1.04 | $7.0M |
| Dec 29, 23 | Anula JayasuriyaDirector | BUY | 10.0K | $1.09 | $11K |
| Mar 31, 22 | Brian M CulleyPresident and CEO | BUY | 6.4K | $1.53 | $10K |
| Mar 28, 22 | Dipti AminDirector | BUY | 35.0K | $1.63 | $57K |
| Mar 25, 22 | Brian M CulleyPresident and CEO | BUY | 5.3K | $1.38 | $7K |
| Mar 25, 22 | Neal C BradsherDirector,TenPercentOwner | BUY | 470.0K | $1.44 | $677K |
| Mar 24, 22 | Michael H. MulroyDirector | BUY | 7.0K | $1.40 | $10K |
| Mar 24, 22 | Neal C BradsherDirector,TenPercentOwner | BUY | 200.0K | $1.42 | $284K |
| Mar 23, 22 | Neal C BradsherDirector,TenPercentOwner | BUY | 260.1K | $1.37 | $356K |
| Dec 29, 21 | Gary S. HoggeSVP,Clinical & Medical Affairs | SELL | 28.4K | $2.49 | $69K |
| Dec 28, 21 | Gary S. HoggeSVP,Clinical & Medical Affairs | SELL | 501.6K | $2.45 | $1.2M |
Over the past 12 months, insiders at Lineage Cell Therapeutics, Inc. filed 1 open-market purchase worth $24K and 0 sales worth $0 on LCTX, which makes them net buyers over the period. The most recent Form 4 was filed on Mar 12, 26.
The largest recent open-market LCTX insider purchase in our data was $7.0M by Broadwood Partners, L.p., Director,TenPercentOwner, filed on Feb 6, 24.
1 different insider at Lineage Cell Therapeutics, Inc. filed open-market SEC Form 4 transactions on LCTX over the last 12 months.
InsiderTape plots every LCTX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Lineage Cell Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →